Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390818 · ClinicalTrials.gov registry record · Phase 1
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 1
- Development phase
- 146
- Enrollment target
NCT01390818 is a Phase 1 study that has completed, run by EMD Serono. The registered enrollment target is 146 participants.
The verdict
NCT01390818, a Phase 1 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 146 participants
- Enrollment target
Study Summary
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advanced or metastatic solid tumors. The primary purpose of the study is to determine the maximum tolerated dose of the drug combination.
Interventions
- DRUG MSC1936369B (pimasertib)
- DRUG SAR245409 (PI3K and mTOR inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01390818
The ClinicalTrials.gov registry entry for NCT01390818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MSC1936369B (pimasertib) is the first listed.
NCT01390818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01390818 about?
NCT01390818 is a clinical study titled "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors". This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advan...
What is the current status of trial NCT01390818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 146 participants. The study started on 2011-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01390818?
The interventions under investigation include: MSC1936369B (pimasertib) (DRUG), SAR245409 (PI3K and mTOR inhibitor) (DRUG).
Who is sponsoring clinical trial NCT01390818?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.